Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLL.L Regulatory News (CLL)

  • There is currently no data for CLL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

15 Sep 2009 07:00

RNS Number : 0378Z
Cello Group plc
15 September 2009
 



15 September 2009

Cello Group plc

Maintaining market share in a challenging environment

Cello Group plc ("CelloAIM: CLL "The Group"), the market research and consulting group, today announces its interim results for the six month period to 30 June 2009.

Highlights

Operating income £30.2m (2008: £33.9m

Headline operating profit £2.5m (2008£4.4m)

Reported operating profit before impairment charges £2.1m (2008: £2.9m)

Interim dividend maintained at 0.50p (20080.50p)

Strong underlying operating cash flow 

Large earnout settlement of £7.7m completed through a mix of cash and sharesEarnout provisions drop by 70% to £4.5m to be settled over next four years

Large client spend remains strong

Brand and property consolidation making good progress

 Mark ScottChief Executive, commented:

"We continue to focus Cello's activity into our primary client verticals of pharmaceutical, healthcare, public sector, and charities where we are achieving competitive advantage and relative scale. We are clearly maintaining our market share in these largely defensive sectors. As part of this process, we are accelerating the consolidation of the business into shared operating hubs behind our larger brands. This is delivering professional benefits for our staff and also reducing overhead. The combination of these activities is strengthening the Group's position for further expansion in the broad healthcare arenin due course".

Enquiries:

Cello Group plc (www.cellogroup.co.uk)

Mark Scott, Chief Executive

020 7812 8460

Mark Bentley, Group Finance Director

Altium

Ben Thorne

020 7484 4040

College Hill

Adrian Duffield/Rozi Morris

020 7457 2020

Notes to Editors (www.cellogroup.co.uk)

Cello is a market research and consulting groupThe Group's strategy is to create value for shareholders by building a research and consulting business able to advise blue chip clients globally, along with a response business capable of delivering world class solutions.

Cello has annualised turnover in excess of £125mannualised operating income in excess of £60m and employs just under 800 professional staff.

Chairman's Statement

Overview

Cello has maintained its market share and continues to benefit from the strength of its blue chip client base. All the Group's large clients have continued to spend significantly against a challenging industry backdrop. The Group's strong position in the pharmaceutical market and in healthcare related sectors has been reinforced

Group income has declined in line with the rest of the sector and pricing pressure remains strong on projects. The Group has therefore continued to bear down on costs to reflect the current trading environment and further reduced its staff numbers. The Group will benefit from property rationalisation in 2010, especially in London, as a result of continued consolidation of operations.

The Group has also substantially settled its earnout commitments during the period. The relatively small commitments that remain are spread over the next four years.

2009 will continue to be a challenging year. However the actions taken in 2008 and 2009 mean that Cello is more focussed, more professionally cohesive, and on a strong financial footing from which to expand in due course.

Financial Review

Turnover for the first six months to 30 June 2009 was £58.0m (2008: £66.1m), and operating income was £30.2m (2008: £33.9m)This like-for-like 10.9% decline in operating income reflects tougher trading conditions in a number of markets compared to the prior periodThe Group'considerable healthcareand public sector client base has remained particularly resilient. In Cello Research and Consulting, areas of weakness were in the HR and business intelligence consultancies. In Tangible, the key area of weakness was in financial services marketing. If these areas are excluded, like-for-like income fell by 6.8%.

Headline operating profit was £2.5m (2008: £4.4m) and reported operating profit before impairment charges was £2.1m (2008: £2.9m). Headline operating margins reduced to 8.4% (200812.9%). Given the drop in income, there has been natural pressure on operating margins. However, this has been mitigated to a significant extent by reductions in staff costs which are 8.1% lower than the same period last year.

Headline pretax profit, after an interest charge of £0.5m (2008: £0.5m), was £2.0m (2008: £3.9m). 

The carrying value of investments is assessed every six months. In the light of continued reduced profit performance from the business intelligence and HR consultancy operations, the Board has substantially reduced their carrying value and reported an exceptional non-cash impairment charge of £5.5m. Therefore the Group has a reported operating loss of £3.4m (2008: profit of £2.9m) and a reported pretax loss of £3.9m (2008: profit of £2.2m).

Headline basic earnings per share was 2.81p (2008: 6.84p). This reflects the decline in profitability in the period and also the dilutive effect of earnout settlements made in the period which required the issuance of 14.2m new shares at 32.5p per share. Reported loss per share was 8.35p (2008: earnings of 3.66p)as a consequence of the non-cash impairment charge.

As a demonstration of the Boards confidence in the Groups prospects, the interim dividend is being maintained at 0.50p per share (2008: 0.50p). It will be paid on 4 November 2009 to all shareholders on the register on 9 October 2009.

The Group's net debt position at the half year was £14.8m (31 December 2008: £9.9m). The increase in debt largely reflects the earnout related cash and loan notes settled in the period. The Group retains a £22.0m total banking facility.

Underlying operating cash flow conversion after cash exceptionals was 77.0%, in line with historical norms, and before a £2.0m surplus reversal that was highlighted in the Group's preliminary results in March.

Provisions for future earnouts have reduced by 71.0% to £4.2m. This follows the regular six monthly review of commitments as well as the £7.7m settlement during the period. It is anticipated that there will be additional future employee related remuneration and additional future notional interest charges over the next four years of £0.3m. This total of £4.5m is anticipated to be split £1.9m in cash and £2.6m in shares, payable over the next four years.

The following table details the adjustments that have been made to calculate headline operating profit. All but the exceptional item are non-cash. The exceptional item relates to redundancy costs incurred during the periodThe Board will continue to tightly control cost and actively manage our resources appropriately

Six months ended 30 June

£m

2009

2008

Headline operating profit

2.5

4.4

Exceptional costs

(0.5)

(0.5)

Share option costs

-

(0.2)

Deemed remuneration

0.3

(0.4)

Amortisation

(0.2)

(0.4)

Reported operating profit before impairment charges

2.1

2.9

Impairment charges

(5.5)

-

Reported operating (loss)/profit

(3.4)

2.9

Review of Operations

The economic conditions continued to adversely impact financial performance across the sector. Despite the recession, the Group has emerged with a strong position in many of its markets, particularly in pharmaceuticalhealthcare and the public sector, which together make up over 40% of Cello's income. In addition, while many other areas of activity have been lower than last year, it is clear that market share has been maintainedAll of the top 20 clients in the first half of 2008 remained as significant clients in the first half of 2009. The client base is broad with the largest client of the Group accounting for only 3.4% of total income, and the top 20 clients accounting for 37.3% of total income

The Group continues its careful programme of brand consolidation. This is most progressed within the Tangible business, and is showing clear benefits in terms of larger mandates and cross business working. 

The Group has taken significant action to reduce the cost base. This is apparent in an 8.1% reduction in total staff costs in the first half of 2009. Going forward into 2010, Cello will also benefit from materially reduced property commitments following action taken on consolidating leases in the first half of 2009 as the Group focuses resources behind bigger operating hubs. The process is ongoing, and there will be further cost reduction action in the second half of the year.

Research and Consulting 

Given the economic context, Cello Research and Consulting had a sound six months, delivering £30.0m of turnover (2008: £33.6m) and £18.2m of operating income (2008: £20.1m). 45.2% of this was from international work. Headline operating profit was £2.3m (2008: £3.7m). Headline operating margins reduced to 12.7% (2008: 18.4%). Excluding the HR and business intelligence consultancies operating margins would have been 15.0%. The balance of the margin decline was accounted for by a foreign currency loss of £0.3m (2008: gain of £0.1m) and a drop in the number of high margin qualitative research briefs.

Cello Research and Consulting has developed its key client relationships, and continues to have a broad client base with a predominantly healthcare orientationPharmaceutical and healthcare accounted for 39.0% of Research and Consulting income (2008: 33.9%). Key clients active in the period included HP, Tesco, Roche, EA, Novartis, GSK, Nokia and Unilever which are all long standing key clients of the business.

Discretionary consulting expenditure proved to be the toughest sub-market. In particular, the HR and business intelligence consultancies had difficult six months. Taking an assessment of future prospects into account, the Board has decided to reduce the carrying value of these assets by £5.5m. This is accounted for as a non-cash exceptional charge.

Tangible

Tangible also had a solid six months, delivering £28.0m of turnover (2008: £32.5m); £12.0m of operating income (2008: £13.8m) and headline operating profit of £0.9m (2008: £1.7m). Headline operating margins fell to 7.3% (2008: 12.0%). If the financial services business is excludedthe operating margin would have been 8.9%, in line with the operating margin in the first half of 2007. The balance of the margin decline was accounted for by across-the-board pricing pressure, particularly with regard to smaller UK-based clients.

The business has maintained its market position in its key areas, and has taken major strides in co-locating businesses, particularly in London where a single office hub now houses six disciplines. One very significant London lease has been vacated, which will positively impact on property costs in 2010.

A key trend in Tangible's income has been a strong six months from the public sector client base. Public sector work accounted for 26.3% of income in the Tangible business (2008: 21.1%). This is very broadly spread over several large clients, including the Scottish Government, the COI, Lifelong Learning and numerous other public sector bodies. 

Financial services income fell from 31.4% of Tangible's income in 2008 to 20.8% in 2009. The larger financial services clients remain actively spending but smaller clients in this area have curtailed activity. The Group has retained key capacity to service this market when it recovers. 

Outlook

While 2009 has so far been a challenging year, the actions on costs taken to date and those in progress in the second half will hold the Group in good stead for the future. Cello has maintained market share and is well positioned in its key client sectors, notably in the pharmaceutical, healthcare and life-style related sectors which are increasingly proving to be the core markets for the Group. 

Encouragingly, it would also appear that the rate of decline in income experienced in the first half has now stabilised, and income visibility remains in line with historical norms. Against this backgroundthe Board currently expects the headline operating profit in the second half of 2009 to exceed the second half of 2008, reflecting the reduced cost base and increased operational focus. 

Allan Rich

Non-Executive Chairman

15 September 2009

Condensed Consolidated Income Statement

for the six months ended 30 June 2009

Notes

Unaudited

Six months ended

30 June 2009

£'000

Unaudited

Six months ended

30 June 2008

£'000

Audited

Year ended

31 December 2008

£'000

Continuing operations

Revenue

3

57,978

66,115

139,127

Cost of sales

(27,797)

(32,237)

(72,543)

Operating income

3

30,181

33,878

66,584

Administration expenses

(27,640)

(29,516)

(58,802)

Headline operating profit

3

2,541

4,362

7,782

Exceptional items

5

(495)

(471)

(1,285)

Amortisation of intangible assets

(266)

(458)

(858)

Acquisition related employee expenses

347

(354)

(647)

Share option credit/(charge)

-

(163)

450

Operating profit before impairment charges

2,127

2,916

5,442

Impairment of intangible assets

(778)

-

-

Impairment of goodwill

9

(4,548)

-

-

Impairment of available-for-sale investments

(162)

-

-

Operating (loss)/profit 

3

(3,361)

2,916

5,442

Finance income

6

12

102

243

Finance cost of deferred consideration

6

(68)

(236)

(291)

Fair value gain/(loss) on derivative financial instruments

6

23

-

(444)

Other finance costs

6

(508)

(558)

(1,134)

(Loss)/profit before taxation

3

(3,902)

2,224

3,816

Tax

7

(290)

(670)

(1,015)

(Loss)/profit for the period

(4,192)

1,554

2,801

 

Attributable to:

Equity holders of parent

(4,206)

1,507

2,761

Minority interest

14

47

40

(4,192)

1,554

2,801

 

Earnings per share

Basic (loss)/earnings per share

8

(8.35)p 

3.66p

6.45p 

Diluted (loss)/earnings per share

8

(8.35)p 

3.39p

4.87p 

Condensed Consolidated Statement of Comprehensive Income

for the six months ended 30 June 2009

Unaudited

Six months ended

30 June 2009

£'000

Unaudited

Six months ended

30 June 2008

£'000

Audited

Year ended

31 December 2008

£'000

Exchange differences on translation of foreign operations

12

-

(47)

Deferred tax recognised direct in equity

-

-

222

Net income/(expense) recognised directly in equity

12

-

175

(Loss)/profit for the period

(4,192)

1,554

2,801

Total recognised (expense)/income for the period

(4,180)

1,554

2,976

 

Condensed Consolidated Balance Sheet

As at 30 June 2009

Notes

Unaudited

At 30 June 2009

£'000

Unaudited

At 30 June 2008

£'000

Audited

At 31 December 2008

£'000

Goodwill

9

69,590

78,950

76,291

Intangible assets

10

1,264

2,592

2,266

Property, plant and equipment

2,859

3,246

3,103

Available-for-sale investments

65

227

227

Deferred tax assets

944

1,664

1,080

Non-current assets

74,722

86,679

82,967

Trade and other receivables

26,621

29,473

26,658

Cash and cash equivalents

4,073

7,448

5,065

Current assets

30,694

36,921

31,723

Trade and other payables

(23,560)

(25,122)

(26,633)

Current tax liabilities

(1,184)

(1,405)

(708)

Borrowings

(3,015)

(6,054)

(1,053)

Consideration payable in respect of acquisitions

11

-

-

(7,980)

Obligations under finance leases

(60)

(56)

(68)

Current liabilities

(27,819)

(32,637)

(36,442)

Net current assets/(liabilities)

2,875

4,284

(4,719)

Total assets less current liabilities

77,597

90,963

78,248

Non-current liabilities

Borrowings

(15,700)

(16,500)

(13,750)

Provisions

11

(4,242)

(17,350)

(6,453)

Obligations under finance leases

(64)

(44)

(86)

Derivative financial instruments

(420)

-

(444)

Deferred tax liabilities

(324)

(757)

(616)

Net assets

56,847

56,312

56,899

Equity

Share capital

12

5,876

4,456

4,456

Share premium

34,945

31,745

31,745

Retained earnings

5,350

8,794

10,048

Capital redemption reserve

50

50

50

Merger reserve

10,496

10,496

10,496

Share-based payment reserve

73

686

73

Foreign currency reserve

(35)

-

(47)

Equity attributable to equity holders of parent

56,755

56,227

56,821

Minority interest

92

85

78

Total equity

56,847

56,312

56,899

Condensed Consolidated Cash Flow Statement

for the six months ended 30 June 2009

Notes

Unaudited

Six months ended

30 June 2009

£'000

Unaudited

Six months ended

30 June 2008

£'000

Audited

Year ended

31 December 2008

£'000

Net cash (outflow)/inflow from operating activities before taxation

13a

(366)

2,281

9,682

Tax received/(paid)

24

(1,547)

(1,911)

Net cash (outflow)/inflow from operating activities after taxation

(342)

734

7,771

Investing activities

Interest received

12

102

243

Purchase of property, plant and equipment

(411)

(646)

(1,119)

Sale of property, plant and equipment

22

32

66

Expenditure on intangible assets

(75)

(46)

(119)

Purchase of subsidiary undertakings

(789)

(3,337)

(3,636)

Net cash outflow from investing activities

(1,241)

(3,895)

(4,565)

Financing activities

Dividends paid to equity holders 

(439)

(334)

(556)

Repayment of bank loan

(650)

(3,550)

(8,050)

Repayment of loan notes

(351)

(179)

(5,211)

Drawdown of borrowings

2,600

8,300

10,050

Capital element of finance lease payments

(30)

(20)

(90)

Payment of finance lease interest

(11)

(11)

(21)

Interest paid

(497)

(512)

(1,105)

Purchase of own shares

(53)

(71)

(71)

Net cash inflow/(outflow) from financing

569

3,623

(5,054)

Movements in cash and cash equivalents

Net (decrease)/increase in cash and cash equivalents

(1,014)

462

(1,848)

Exchange gains/(losses) on cash and bank overdrafts

22

-

(73)

Cash and cash equivalents at the beginning of the period

5,065

6,986

6,986

Cash and cash equivalents at end of the period

4,073

7,448

5,065

Condensed Consolidated Statement of Changes in Equity

for the six months ended 30 June 2009

Statement of changes in equity for the six months ended 30 June 2009:

Share 

Capital

£'000

Share Premium

£'000

Capital Redemption Reserve

£'000

Merger Reserve

£'000

Share-based Payment Reserve

£'000

Foreign 

Currency Translation Reserve

£'000

Retained Earnings

£'000

Total

£'000

Minority Interest

£'000

Total Equity

£'000

Loss for the year

-

-

-

-

-

-

(4,206)

(4,206)

14

(4,192)

Currency translation

-

-

-

-

-

12

-

12

-

12

Total recognised income in the period

-

-

-

-

-

12

(4,206)

(4,194)

14

(4,180)

At 1 January 2009

4,456

31,745

50

10,496

73

(47)

10,048

56,821

78

56,899

Shares issued

1,420

3,200

-

-

-

-

-

4,620

-

4,620

Own shares purchased

-

-

-

-

-

-

(53)

(53)

-

(53)

Dividends paid

-

-

-

-

-

-

(439)

(439)

-

(439)

As at 30 June 2009 (unaudited)

5,876

34,945

50

10,496

73

(35)

5,350

56,755

92

56,847

Statement of changes in equity for the six months ended 30 June 2008:

Share 

Capital

£'000

Share Premium

£'000

Capital Redemption Reserve

£'000

Merger Reserve

£'000

Share-based Payment Reserve

£'000

Foreign 

Currency Translation Reserve

£'000

Retained Earnings

£'000

Total

£'000

Minority Interest

£'000

Total Equity

£'000

Profit for the year

-

-

-

-

-

-

1,507

1,507

47

1,554

Total recognised income in the period

-

-

-

-

-

-

1,507

1,507

47

1,554

At 1 January 2008

3,884

25,776

50

10,496

523

-

7,692

48,421

38

48,459

Shares issued

572

5,969

-

-

-

-

6,541

-

6,541

Own shares purchased

-

-

-

-

-

(71)

(71)

-

(71)

Credit for share-based incentive schemes

-

-

-

-

163

-

-

163

-

163

Dividends paid

-

-

-

-

-

-

(334)

(334)

-

(334)

As at 30 June 2008 (unaudited)

4,456

31,745

50

10,496

686

-

8,794

56,227

85

56,312

 Statement of changes in equity for the year ended 31 December 2008: 

Share 

Capital

£'000

Share Premium

£'000

Capital Redemption Reserve

£'000

Merger Reserve

£'000

Share-based Payment Reserve

£'000

Foreign 

Currency Translation Reserve

£'000

Retained Earnings

£'000

Total

£'000

Minority Interest

£'000

Total Equity

£'000

Profit for the year

-

-

-

-

-

-

2,761

2,761

40

2,801

Currency translation

-

-

-

-

-

(47)

-

(47)

-

(47)

Deferred tax recognised directly in equity

-

-

-

-

-

-

222

222

-

222

Total recognised income  in the year

-

-

-

-

-

(47)

2,983

2,936

40

2,976

At 1 January 2008

3,884

25,776

50

10,496

523

-

7,692

48,421

38

48,459

Shares issued

572

5,969

-

-

-

-

-

6,541

-

6,541

Own shares purchased

-

-

-

-

-

-

(71)

(71)

-

(71)

Debit for share-based incentive schemes

-

-

-

-

(450)

-

-

(450)

-

(450)

Dividends paid

-

-

-

-

-

-

(556)

(556)

-

(556)

As at 31 December 2008

4,456

31,745

50

10,496

73

(47)

10,048

56,821

78

56,899

Notes to the Financial Information

for the six months ended 30 June 2009

1. ACCOUNTING POLICIES AND BASIS OF PREPARATION

The condensed consolidated financial information for the six months ended 30 June 2009 has been prepared in accordance with IAS 34 Interim Financial Reporting, as adopted by the European Union. The condensed consolidated financial information should be read in conjunction with the annual financial statements for the year ended 31 December 2008, which have been prepared in accordance with IFRSs as adopted by the European Union.

The accounting policies applied are consistent with those of the annual financial statements for the year ended 31 December 2008, as described in those annual financial statements.

The condensed consolidated financial information does not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006. Statutory accounts for the year ended 31 December 2008 were approved by the Board of directors on 16 March 2009 and delivered to the Registrar of Companies. The report of the auditors on those accounts was unqualified, did not contain an emphasis of matter paragraph and did not contain any statement under section 237 of the Companies Act 1985.

The condensed consolidated financial information was approved for issue on 14 September 2009 and has not been audited.

The following new standards and amendments are mandatory for the first time for the financial year beginning 1 January 2009.

IAS 1 (revised) Presentation of Financial Statements. The revised statement prohibits the presentation of items of income and expense (that is 'non-owner changes in equity') in the statement of changes in equity, requiring the 'non-owner changes in equity' to be presented separately from owner changes in equity. All 'non-owner changes in equity' are required to be shown in a performance statement.

Entities can choose whether to present one performance statement (the statement of comprehensive income) or two statements (the income statement and statement of comprehensive income).

The Group has elected to present two statements: an income statement and a statement of comprehensive income. The financial statements have been prepared under the revised disclosure requirements.

IFRS 8 Operating Segments. IFRS 8 replaces IAS 14 Segment Reporting. It requires a 'management approach' under which segment information is presented on the same basis as that used for internal reporting purposes. This has not resulted in a change in the number of reportable segments.

2. SIGNIFICANT ACCOUNTING POLICIES

(a) Revenue, Cost of Sales and Revenue Recognition

Revenue is recognised as contract activity progresses, in accordance with the terms of the contractual agreement and the stage of completion of the work. It is in respect of the provision of services including fees, commissions, rechargeable expenses and sales of materials performed subject to specific contract. Where recorded revenue exceeds amounts invoiced to clients, the excess is classified as accrued income and where recorded revenue is less than amounts invoiced to clients, the difference is classified as deferred income.

Cost of sales include amounts payable to external suppliers where they are retained at the Group's discretion to perform part of a specific client project or service where the Group has full exposure to the benefits and risks of the contract with the client.

(b) Goodwill and Intangible Assets

In accordance with IFRS 3 Business Combinations, goodwill arising on acquisitions is capitalised as an intangible asset. Other intangible assets are also identified and amortised over their useful economic lives on a straight line basis. Examples of these are licences to trade, and client contracts. The useful economic lives vary from 3 months to 8 years. Goodwill is not amortised.

Under IAS 36 Impairment of Assets, the carrying values of all intangible assets are reviewed bi-annually for impairment on the basis stipulated in IAS 36 and adjusted to the recoverable amount. Typically, such a review will entail an assessment of the present value of projected returns from the asset over a 3-5 year projection period, and inflation based growth assumptions for subsequent years, to a maximum period of 20 years.

(c) Share-Based Payments

The Group has applied the requirements of IFRS 2 Share-based Payment which requires the fair value of share-based payments to be recognised as an expense. In accordance with the transitional provisions, IFRS 2 been applied to such equity instruments that were granted after 7 November 2002 and which had not vested by 1 January 2006.

This standard has been applied to various types of share-based payments as follows:

i.  Share options

Certain employees receive remuneration in the form of share options. The fair value of the equity instruments granted is measured on the date at which they are granted by using the Black Scholes model, and is expensed to the income statement over the appropriate vesting period.

ii. Acquisition related employee remuneration expenses

In accordance with IFRS 3 Business Combinations and IFRS 2 Share-based Payment, certain payments to employees in respect of earn out arrangements are treated as remuneration within the income statement.

(d) Exceptional Items

Exceptional items are those items which, because of their nature and materiality, merit separate presentation to allow a better understanding of the Groups' financial performance.

3. SEGMENTED INFORMATION

6 months ended 30 June 2009

Research and

Consulting

£'000

Tangible Group

£'000

Unallocated Corporate Expenses

£'000

Group

£'000

Profit and loss

Revenue

29,976

28,002

-

57,978

Operating income

18,188

11,993

-

30,181

Headline operating profit (headline segment result)

2,316

877

(652)

2,541

Exceptional items

(224)

(271)

-

(495)

Amortisation of intangible assets

(201)

(65)

-

(266)

Acquisition related employee expenses

293

54

-

347

Operating profit before impairments

2,184

595

(652)

2,127

Impairment of intangible assets

(778)

-

-

(778)

Impairment of goodwill

(4,548)

-

-

(4,548)

Impairment of available-for-sale investments

(162)

-

-

(162)

Operating profit (segment result)

(3,304)

595

(652)

(3,361)

Financing income

12

Finance costs

(508)

Fair value gain on derivative financial instruments

23

Finance cost of deferred consideration

(68)

Profit before tax

(3,902)

Other information 

apital expenditure

174

237

-

411

Capitalisation of intangible assets

-

75

-

75

Depreciation of property, plant and equipment

348

278

6

632

Research and

Consulting

£'000

Tangible Group

£'000

Unallocated Corporate Assets/ (Liabilities)

£'000

Eliminations

£'000

Total

£'000

Assets and liabilities

Assets

60,165

49,088

3,128

(7,909)

104,472

Deferred tax assets

944

Consolidated total assets

105,416

Liabilities

(12,361)

(15,557)

(8,213)

7,909

(28,222)

Borrowings

(18,715)

Corporation tax liabilities

(1,184)

Deferred tax liabilities

(324)

Finance leases

(124)

Consolidated total liabilities

(48,569)

6 months ended 30 June 2008 

Research and

Consulting

£'000

Tangible Group

£'000

Unallocated Corporate Expenses

£'000

Group

£'000

Profit and loss 

Revenue

33,572

32,543

-

66,115

Operating income

20,078

13,800

-

33,878

Headline operating profit (headline segment result)

3,692

1,656

(986)

4,362

Exceptional items

(238)

(231)

(2)

(471)

Amortisation of intangible assets

(314)

(144)

-

(458)

Acquisition related employee expenses

(189)

(165)

-

(354)

Share option charges

(11)

(1)

(151)

(163)

Operating profit (segment result)

2,940

1,115

(1,139)

2,916

Financing income

102

Finance costs

(236)

Finance cost of deferred consideration

(558)

Profit before tax

2,224

Other information 

Capital expenditure

362

284

-

646

Capitalisation of intangible assets

-

46

-

46

Depreciation of property, plant and equipment

399

275

3

677

Research and

Consulting

£'000

Tangible Group

£'000

Unallocated Corporate Assets/ (Liabilities)

£'000

Eliminations

£'000

Total

£'000

Assets and liabilities

Assets

72,151

48,590

7,208

(6,013)

121,936

Deferred tax assets

1,664

Consolidated total assets

123,600

Liabilities

(24,653)

(17,289)

(6,543)

6,013

(42,472)

Borrowings

(22,554)

Corporation tax liabilities

(1,405)

Deferred tax liabilities

(757)

Finance leases

(100)

Consolidated total liabilities

(67,288)

for the year ended 31 December 2008

Research and

Consulting

£'000

Tangible Group

£'000

Unallocated Corporate Expenses

£'000

Group

£'000

Profit and loss

Revenue

66,415

72,712

-

139,127

Operating income

39,084

27,500

-

66,584

Headline operating profit (headline segment result)

6,122

3,708

(2,048)

7,782

Exceptional items

(521)

(724)

(40)

(1,285)

Amortisation of intangible assets

(611)

(247)

-

(858)

Acquisition related employee expenses

(419)

(228)

-

(647)

Share option credit

98

78

274

450

Operating profit (segment result)

4,669

2,587

(1,814)

5,442

Financing income

243

Finance costs

(1,134)

Fair value loss on derivative financial instruments

(444)

Finance cost of deferred consideration

(291)

Profit before tax

3,816

Other information 

Capital expenditure

742

501

-

1,243

Capitalisation of intangible assets

-

119

-

119

Depreciation of property, plant and equipment

843

560

-

1,403

Research and

Consulting

£'000

Tangible Group

£'000

Unallocated Corporate Assets/ (Liabilities)

£'000

Eliminations

£'000

Total

£'000

Assets and liabilities

Assets

69,055

48,675

2,412

(6,532)

113,610

Deferred tax assets

1,080

Consolidated total assets

114,690

Liabilities

(23,451)

(17,282)

(7,308)

6,532

(41,509)

Borrowings

(14,803)

Corporation tax liabilities

(708)

Deferred tax liabilities

(616)

Finance leases

(155)

Consolidated total liabilities

(57,791)

4.  DIVIDEND 

An interim dividend of 0.5p (2008: 0.5p) per ordinary share is declared and will be paid on 4 November 2009 to all shareholders on the register on 9 October 2009. In accordance with IAS 10 Events after the Balance Sheet Date, this dividend has not been recognised in the accounts at 30 June 2009, but will be recognised in the accounting period ending 31 December 2009.

5.  EXCEPTIONAL ITEMS

Exceptional items are redundancy costs incurred in the period which have a material effect on the results. These costs have been separately disclosed in order to assist in understanding the financial performance.

6.  FINANCE INCOME AND COSTS

Unaudited

Six months ended

30 June 2009

£'000

Unaudited

Six months ended

30 June 2008

£'000

Audited 

Year ended 

31 December 2008

£'000

Finance income:

Interest receivable on bank deposits

12

102

243

Fair value gains on derivative financial instruments

23

-

-

35

102

243

Finance costs:

Interest payable on bank loans and overdrafts

317

505

974

Interest payable on loan notes

-

42

139

Interest payable in respect of finance leases

11

11

21

Finance costs on cap and collar interest rate hedge

180

-

-

508

558

1,134

Notional finance costs on future deferred consideration

68

236

291

Fair value loss on derivative financial instruments

-

-

444

576

794

1,869

7.  TAXATIOON PROFIT OORDINARY ACTIVITIES

The tax charge for the half year ended 30 June 2009 has been based on an estimated effective tax rate on profit on ordinary activities for the full year of 28.0% (year ended 31 December 200828.5%), adjusted for expenses not deductible for tax purposes, such as impairment of goodwill and finance costs of deferred remuneration.

8  (LOSS)/EARNINGS PER SHARE

Unaudited

Six months ended

30 June 2009

£'000

Unaudited

Six months ended

30 June 2008

£'000

Audited 

Year ended 

31 December 2008

£'000

Basic and diluted (losses)/earnings attributable to ordinary shareholders

(4,206)

1,507

2,761

Adjustments to (losses)/earnings:

Exceptional items

495

471

1,285

Amortisation of intangibles

266

458

858

Impairment of intangible assets

778

-

-

Impairment of goodwill

4,548

-

-

Impairment of available-for-sale investments

162

-

-

Share-based payments expense

-

163

(450)

Acquisition related employee remuneration expenses

(347)

354

647

Fair value loss on derivative financial instruments

(23)

-

444

Notional finance costs on future deferred consideration payments

68

236

291

Tax thereon

(327)

(373)

(618)

Adjusted earnings attributable to ordinary shareholders

1,414

2,816

5,218

Number

Number

Number

Weighted average number of ordinary shares

50,380,210

41,163,500

42,831,617

Dilutive effect of securities:

Share options

-

-

-

Deferred consideration shares to be issued

8,230,932

3,323,048

13,823,781

Diluted weighted average number of ordinary shares

58,611,142

44,486,548

56,655,398

Further dilutive effect of securities:

Share options

-

1,471,504

-

Contingent consideration shares to be issued

5,987,909

14,016,244

9,964,568

Fully diluted weighted average number of ordinary shares

64,599,051

59,974,296

66,619,966

Basic (loss)/earnings per share

(8.35)p

3.66p

6.45p

Diluted (loss)/earnings per share

(8.35)p

3.39p

4.87p

Fully diluted (loss)/earnings per share

(8.35)p

2.51p

4.14p

Headline basic earnings per share

2.81p

6.84p

12.18p

Headline diluted earnings per share

2.41p

6.33p

9.21p

Headline fully diluted earnings per share

2.19p

4.70p

7.83p

Headline earnings per share and fully diluted earnings per share have been presented to provide additional information which may be useful to the readers of this statement.

Basic (loss)/earnings per share is calculated by dividing the earnings attributable to ordinary shareholders by the weighted average number of ordinary shares in issue during the period, excluding treasury shares, determined in accordance with the provisions of IAS 33 Earnings per Share.

Diluted (loss)/earnings per share is calculated by dividing earnings attributable to ordinary shareholders by the weighted average number of ordinary shares in issue during the year adjusted for the potentially dilutive ordinary shares for which the conditions of issue have substantially been met but not issued at the end of the period. Given the loss in the period to 30 June 2009, the effect of these potentially dilutive ordinary shares are anti-dilutive so dilutive earnings per share is deemed to equal basic earnings per share.

Fully diluted (loss)/earnings per share is calculated by adjusting the weighted average number of ordinary shares in issue on the assumption of conversion of all the potentially dilutive ordinary shares. Given the loss in the period to 30 June 2009, the potentially dilutive shares are anti-dilutive so fully dilutive earnings per share is deemed to equal basic earnings per share.

The Group has two categories of potential dilutive shares, being share options granted where the exercise price is less than the average price of the Company's ordinary shares during the period and shares to be issued as contingent consideration on completed acquisitions.

9  GOODWILL

Unaudited

At 30 June 2009

£'000

Unaudited

At 30 June 2008

£'000

Audited 

At 31 December 2008

£'000

Cost

At 1 January 2009

76,291

77,912

77,912

Goodwill arising on acquisitions in the period

49

-

-

Adjustment to fair value of deferred consideration

(2,202)

1,038

(1,621)

Impairment of goodwill

(4,548)

-

-

At 30 June 2009

69,590

78,950

76,291

The adjustment to the fair value of deferred consideration relates to changes in estimate of deferred consideration payable under earnout arrangements in accordance with the terms of the relevant acquisition agreements. Adjustment to the value of assets acquired relate to fair value adjustments of the net assets acquired on acquisitions in the prior period.

Following a review of the carrying values of goodwill, an impairment charge of £3,631,000 has been made on the value of goodwill in SMT Consulting Limited ("SMT"), the Group's business intelligence unit, due to reduced trading performance in the current economic environment. The resulting value of goodwill in SMT is held at its recoverable amount on a value-in-use basis, using projected returns over the next 4 years and inflation based growth assumption for a further 16 years. The returns are discounted to present value using a discount rate of 5.8% (year ended 31 December 2008: 5.8%).

An impairment charge of £917,000 has also been made to the value of goodwill in Chairos Holdings Limited ("Chairos"), the Group's HR consultancy business, due to reduced trading performance in the current economic environment. The resulting value of goodwill in Chairos is held at its recoverable amount on a value-in-use basis, using projected returns over the next 4 years and an inflation based growth assumption for a further 7 years. The returns are discounted to present value using a discount rate of 5.2% (year ended 31 December 2008: 5.2%).

10. INTANGIBLE ASSETS

Following a review of the carrying value of the licence held by Chairosan impairment charge of £778,000 has been made to the carrying value of the licence, due to reduced trading performance in the current economic environment. The resulting value of the licence is held at its recoverable amount on a value-in-use basis, using projected returns over the next 4 years and an inflation based growth assumption for a further 7 years. The returns are discounted to present value using a discount rate of 5.2% (year ended 31 December 2008: 5.2%).

11. DEFERRED CONSIDERATION FOR ACQUISITIONS

Unaudited

At 30 June 2009

£'000

Unaudited

At 30 June 2008

£'000

Audited 

At 31 December 2008

£'000

Current liabilities

-

-

7,980

Provisions 

4,242

17,350

6,453

4,242

17,350

14,433

Movements in the period can be analysed as follows:

Unaudited

Six months ended

30 June 2009

£'000

Unaudited

Six months ended

30 June 2008

£'000

Audited 

Year ended 

31 December 2008

£'000

At 1 January 2009

14,433

30,581

30,581

Payments made in the period

(7,710)

(14,926)

(15,240)

Additions in the period

-

-

-

Adjustment to provisions of additions in prior periods

(2,202)

1,105

(1,846)

Acquisition related employee remuneration expense

(347)

354

647

Notional finance costs on future deferred consideration payments

68

236

291

At 30 June 2009

4,242

17,350

14,433

Make up of contingent consideration is as follows:

Earnout related cash payables

1,731

7,192

5,790

Shares to be issued

2,511

10,158

8,643

4,242

17,350

14,433

Earnout payments are to be in cash and shares. In the analysis above the minimum percentage of cash has been assumed. However, at the Group's sole discretion, this percentage can be increased.

12.  SHARE CAPITAL

Unaudited

At 30 June 2009

£'000

Unaudited

At 30 June 2008

£'000

Audited 

At 31 December 2008

£'000

Authorised:

84,600,000 ordinary shares of 10p each

8,460

6,500

6,500

Allotted, issued and fully paid

58,762,197 ordinary shares of 10p each

5,876

4,456

4,456

During the interim period 14,200,594 ordinary shares of 10p each were issued as part of the earnout consideration for acquisitions.

13.  NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT

(a) Reconciliation of operating profit to net cash (outflow)/inflow from operating activities

Unaudited

Six months ended

30 June 2009

£'000

Unaudited

Six months ended

30 June 2008

£'000

Audited 

Year ended 

31 December 2008

£'000

(Loss)/profit for the period

(4,192)

1,554

2,801

Finance income

(12)

(102)

(243)

Finance costs of deferred consideration 

68

236

291

Fair value (gain)/loss on derivative financial instruments 

(24)

-

444

Other finance costs 

508

558

1,134

Tax

290

670

1,015

Depreciation 

632

677

1,403

Amortisation of intangible assets

299

458

858

Impairment of intangible assets

778

-

-

Impairment of goodwill

4,548

-

-

Impairment of available-for-sale investments

162

-

-

Share-based payment expense

-

163

(450)

Acquisition related employee remuneration expense

(347)

354

647

Profit on disposal of property, plant and equipment

3

(32)

(48)

Decrease/(increase) in receivables

67

(753)

2,062

Decrease in payables

(3,146)

(1,502)

(232)

Net cash (outflow)/inflow from operating activities

(366)

 

2,281

 

9,682

(b) Analysis of net debt

At 1 January 2009

£'000

Cash flow

£'000

Issue of debt

£,000

Foreign exchange

£,000

At 30 June 2009

£'000

Cash and cash equivalents

5,065

(1,014)

-

22

4,073

Loan notes 

(1,053)

351

(2,313)

-

(3,015)

Bank loans 

(13,750)

(1,950)

-

-

(15,700)

Finance leases

(154)

30

-

-

(124)

(9,892)

(2,583)

(2,313)

22

(14,766)

  

  

  

During the period there were the following issuances and repayments of debt:

£2.60m was drawn down from the Group's loan facility to fund the cash element of acquisitions made in the period.

£0.65m of the Group's loan facility was repaid from the Group's cash reserves.

£2.31m of secured loan notes were issued as part of the consideration for acquisitions in the period.

14.   INTERIM STATEMENT

This statement does not constitute full statutory financial statements within the meaning of section 434 of the Companies Act 2006.

15.  REGULATORY DISCLOSURE

In accordance with schedule two, paragraph (g) of the AIM Rules, Cello announces that Chris Outram, a non-executive director of Cello, is also a director of ActionLeisure plc. An administration order was made against ActionLeisure plc on 11 October 2001 and that company remains in administration.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR LIMFTMMTBBJL
Date   Source Headline
11th Aug 20201:38 pmRNSForm 8.3 - Cello Health Plc
11th Aug 202012:05 pmRNSForm 8.3 - Cello Health Plc
11th Aug 202011:34 amRNSForm 8.3 - [Cello Health plc]
11th Aug 202010:07 amRNSScheme of Arrangement becomes Effective
11th Aug 20208:49 amPRNForm 8.3 - Cello Health Plc
11th Aug 20207:30 amRNSSuspension - Cello Health Plc
10th Aug 20202:30 pmRNSForm 8 (DD) - Cello Health plc
10th Aug 20202:30 pmRNSForm 8 (DD) - Cello Health plc
10th Aug 20202:30 pmRNSForm 8 (DD) - Cello Health plc
10th Aug 20202:30 pmRNSForm 8 (DD) - Cello Health plc
10th Aug 202012:12 pmRNSRelevant Securities in Issue
10th Aug 202011:02 amRNSForm 8.3 - Cello Health PLC
10th Aug 20208:54 amRNSExercise of Options
10th Aug 20208:06 amRNSForm 8.5 (EPT/NON-RI)
7th Aug 20203:16 pmRNSForm 8.3 - CELLO HEALTH PLC
7th Aug 20203:04 pmRNSCourt Sanction of Scheme
7th Aug 202012:52 pmRNSAdditional Block Listing of Ordinary Shares
6th Aug 202011:01 amRNSForm 8.3 - Cello Health PLC
5th Aug 20201:34 pmRNSForm 8.3 - Cello Health Plc
4th Aug 20205:30 pmRNSCello Health
4th Aug 202012:39 pmRNSForm 8.3 - Cello Health PLC
4th Aug 20208:21 amRNSForm 8.5 (EPT/NON-RI)
3rd Aug 202012:57 pmRNSResults of Court Meeting and General Meeting
3rd Aug 202010:53 amRNSForm 8.3 - CELLO GROUP PLC
31st Jul 202012:39 pmRNSForm 8.3 - CELLO GROUP PLC
31st Jul 202011:46 amRNSForm 8.3 - Cello Health PLC
31st Jul 20208:34 amRNSForm 8.5 (EPT/NON-RI)
31st Jul 20207:58 amRNSForm 8.3 - Cello Health PLC
30th Jul 20205:11 pmRNSHolding(s) in Company
30th Jul 20208:03 amRNSForm 8.3 - Cello Health Plc
29th Jul 202012:49 pmRNSHolding(s) in Company
29th Jul 20208:30 amRNSForm 8.5 (EPT/NON-RI)
28th Jul 20206:18 pmRNSUpdate on letters of intent
28th Jul 20203:17 pmRNSForm 8.3 - CELLO HEALTH PLC
28th Jul 20202:46 pmRNSForm 8.3 - Cello Health PLC
28th Jul 20202:04 pmRNSNotification of Major Holdings
28th Jul 20201:24 pmRNSCELLO HEALTH PLC ORD GBP0.10
28th Jul 202011:36 amGNWForm 8.3 - [Cello Health plc] - (HHL)
28th Jul 202011:17 amRNSForm 8.3 - Cello Health Plc
28th Jul 20208:45 amRNSForm 8.5 (EPT/NON-RI)
27th Jul 20203:17 pmRNSForm 8.3 - [CELLO HEALTH PLC
27th Jul 20207:00 amRNSHolding(s) in Company
23rd Jul 20203:29 pmRNSForm 8.3 - Cello Health PLC
22nd Jul 202012:33 pmRNSForm 8.3 - Cello Health PLC
22nd Jul 202011:38 amRNSFORM 8.3 - Cello Health Plc
21st Jul 20203:15 pmBUSForm 8.3 - Cello Health plc
21st Jul 20202:35 pmRNSForm 8.3 - Cello Health PLC
21st Jul 202012:18 pmRNSBlock Listing Update & Total Voting Rights
21st Jul 20207:00 amRNSHolding(s) in Company
20th Jul 20203:15 pmBUSForm 8.3 - Cello Health plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.